EMA 更新 Vabysmo（faricimab）欧洲公众评估报告：第11版，维持用于湿性AMD、糖尿病性黄斑水肿及RVO相关黄斑水肿
EMA 发布 Vabysmo（faricimab）第11版 EPAR，该药于2022年9月15日获批，用于治疗湿性年龄相关性黄斑变性（AMD）、糖尿病性黄斑水肿及视网膜静脉阻塞（RVO）引起的黄斑水肿。
#Roche
EMA · What's New
PubMed · Vaccine 公共卫生：Cross-protection and type-replacement over the 17 years after human papillomavirus vaccine introduction in young women.
原文摘录：BACKGROUND: The study aim was to examine trends in non-4-valent and non-9-valent vaccine-type HPV detection over the first 17 years after U.S. HPV vaccine introduction among young women. … CONCLUSIONS: We did not find evidence for cross-protection against types not targeted by the 4-valent or 9-valent vaccines, but did find a signal for possible emerging type replacement